Toriola, Mubaraq A, Timlin, Emma, Bulbule, Sarojini et al. · Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026 · DOI
This study examined a protein called ATG13 that helps cells clean up damaged parts, particularly in immune cells called macrophages. When ATG13 was reduced, these immune cells couldn't work properly, their energy-producing structures (mitochondria) became dysfunctional, and they created too much harmful oxidative stress. This triggered the immune cells to switch into an inflammatory state and caused muscle weakness and nerve damage in a mouse model.
This study identifies a potential molecular mechanism linking cellular autophagy dysfunction to excessive inflammation and post-exertional malaise—a hallmark symptom of ME/CFS where patients experience severe fatigue following minor exertion. Understanding how ATG13 deficiency leads to immune dysregulation and mitochondrial dysfunction could guide development of targeted therapies for ME/CFS patients who currently have no curative treatments.
This study does not prove that ATG13 mutations or deficiency cause ME/CFS in humans, as it uses a genetically engineered mouse model with artificially depleted ATG13. The findings do not establish whether ATG13 dysfunction is a primary cause versus a consequence of ME/CFS pathology. It also does not demonstrate that correcting ATG13 expression would reverse symptoms in human patients.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →